ADReCS

Pharmaceutical Information

Drug Name	Crizotinib
Drug ID	BADD_D00535
Description	Crizotinib an inhibitor of receptor tyrosine kinase for the treatment of non-small cell lung cancer (NSCLC). Verification of the presence of ALK fusion gene is done by Abbott Molecular's Vysis ALK Break Apart FISH Probe Kit. This verification is used to select for patients suitable for treatment. FDA approved in August 26, 2011.
Indications and Usage	Crizotinib is used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic-lymphoma kinase (ALK)-positive as detected by a FDA-approved test.
Marketing Status	approved
ATC Code	L01ED01
DrugBank ID	DB08865
KEGG ID	D09731
MeSH ID	D000077547
PubChem ID	11626560
TTD Drug ID	D03ZBT
NDC Product Code	68724-1020; 53869-2231; 53869-2230; 0069-8140; 0069-8141
UNII	53AH36668S
Synonyms	Crizotinib \| PF-02341066 \| PF-2341066 \| PF 2341066 \| PF2341066 \| PF 02341066 \| PF02341066 \| Xalkori

Chemical Information

Molecular Formula	C21H22Cl2FN5O
CAS Registry Number	877399-52-5
SMILES	CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N
Chemical Structure

ADRs Induced by Drug

*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..

ADR Term	ADReCS ID	ADR Frequency (FAERS)	ADR Severity Grade (FAERS)	ADR Severity Grade (CTCAE)
Hypocalcaemia	14.04.01.004	0.000280%
Hypokalaemia	14.05.03.002	-	-
Hyponatraemia	14.05.04.002	0.001007%
Hypophosphataemia	14.04.03.001	-	-
Hypoproteinaemia	14.10.01.003; 09.01.02.004	0.000336%		Not Available
Hypoxia	22.02.02.003	0.000895%
Ileus	07.13.01.001	0.000336%
Impaired gastric emptying	07.02.02.004	0.000168%
Increased appetite	14.03.01.003; 08.01.09.027	0.000302%		Not Available
Infection	11.01.08.002	-	-	Not Available
Insomnia	19.02.01.002; 17.15.03.002	-	-
Interstitial lung disease	22.01.02.003; 10.02.01.033	0.003246%		Not Available
Intestinal obstruction	07.13.01.002	0.000392%		Not Available
Intestinal perforation	07.04.06.002	0.000336%		Not Available
Jaundice	23.03.03.030; 09.01.01.004; 01.06.04.004	0.000448%		Not Available
Joint swelling	15.01.02.004	0.003324%		Not Available
Large intestine perforation	12.02.03.005; 07.04.06.005	0.000336%
Laryngeal oedema	23.04.01.005; 22.04.02.001; 10.01.05.003	0.000168%
Leukoencephalopathy	17.13.02.003	0.000112%
Leukopenia	01.02.02.001	0.001086%		Not Available
Lip oedema	07.05.04.004; 23.04.01.006; 10.01.05.004	0.000302%		Not Available
Liver disorder	09.01.08.001	0.002127%		Not Available
Loss of consciousness	17.02.04.004	-	-	Not Available
Lung disorder	22.02.07.001	0.000728%		Not Available
Lung infiltration	22.01.02.004	0.000414%		Not Available
Lymphoedema	24.09.01.001; 01.09.01.006	0.000246%
Lymphoma	01.12.01.001; 16.20.01.001	0.000168%		Not Available
Lymphopenia	01.02.02.002	0.000392%		Not Available
Mass	08.03.05.003	0.000112%		Not Available
Metastases to lung	16.22.02.002; 22.08.01.005	0.000168%		Not Available

The 5th Page First Pre 5 6 7 8 9 Next Last Total 13 Pages